What is MatTek?
Founded in 1985 by researchers from the Massachusetts Institute of Technology, MatTek has established itself as a cornerstone provider of 3D human tissue models and specialized cell culture products. By offering high-fidelity alternatives to traditional animal testing, the company serves a diverse array of scientific disciplines, including ocular, respiratory, and dermal studies. As a subsidiary of Sartorius, MatTek leverages significant operational synergies to maintain its position at the forefront of ethical, human-relevant science, ensuring that researchers worldwide have access to tools that provide superior imaging clarity and physiological accuracy.
How much funding has MatTek raised?
MatTek has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in MatTek
PPP
Public-Private Partnership
What's next for MatTek?
With the support of this major enterprise-level funding, MatTek is positioned to accelerate its research and development pipeline, focusing on the expansion of its tissue engineering capabilities. The strategic allocation of this capital will likely prioritize the scaling of manufacturing infrastructure to meet the rising global demand for non-animal testing methodologies. As regulatory bodies increasingly favor human-relevant data, MatTek's trajectory suggests a continued expansion into new therapeutic areas, further cementing its role as an indispensable partner for global pharmaceutical firms and academic institutions seeking to optimize their drug discovery and safety assessment workflows.
See full MatTek company page
